Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 9.6% from a year ago
Total equity stood at $42.1M at the end of Q1 FY2026, up 9.6% from a year earlier and down 31.0% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Total equity amounted to 62.6% of total assets at the end of Q1 FY2026, down 18.3 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +9.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 60.99M USD
- Year-over-year change
- +16.2%
- 4-year CAGR
- +10.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.99M | +16.2% |
| FY2024 | 2024-12-31 | 52.48M | +48.6% |
| FY2023 | 2023-12-31 | 35.31M | -9.0% |
| FY2022 | 2022-12-31 | 38.82M | -6.6% |
| FY2021 | 2021-12-31 | 41.55M | — |
Total Equity vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +9.6% is the 3rd highest of 10, against a peer median of -37.7%.
- Total equity amounts to 62.6% of total assets for FBRX, versus a peer median of 70.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $285.86M USD | -24.5% | -5.7% | 76.8% | |
| Mar 2026 | $179.71M USD | -37.7% | -24.6% | 63.1% | |
| Mar 2026 | $133.98M USD | +45.9% | -6.4% | 85.7% | |
| Mar 2026 | $126.34M USD | -0.6% | +64.7% | 87.4% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $42.1M USD | +9.6% | +16.3% | 62.6% | |
| Mar 2026 | $34.71M USD | -51.0% | -24.7% | 70.6% | |
| Mar 2026 | $10.38M USD | -89.0% | -47.7% | 4.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.78M USD | +174.4% | -18.9% | 42.5% |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$1.44M USD | -116.1% | -43.2% | 6.3% |
| Peer median (excluding FBRX) | — | -37.7% | -24.6% | 70.6% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.